


产品名称：利西拉来
产品别名：Lixisenatide

生物活性：						
Description	Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).					
IC₅₀ & Target	GLP-1 receptor[1][2].					
Solvent&Solubility	In Vitro: H ₂ O : 106 mg/mL (21.82 mM; Need ultrasonic and warming)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		0.2058 mL	1.0291 mL	2.0583 mL
		5 mM		0.0412 mL	0.2058 mL	0.4117 mL
		10 mM		0.0206 mL	0.1029 mL	0.2058 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。					
References	<p>[1]. Ahrén B et al. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. <i>Diabetes Ther.</i> 2016 Jun 18</p> <p>[2]. Lorenz M, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia. <i>Regul Pept.</i> 2013 Aug 10;185:1-8.</p>					



源叶生物